HK1201471A1 - 用於治疗和/或预防天然ahr配体依赖性癌症的手段和方法 - Google Patents

用於治疗和/或预防天然ahr配体依赖性癌症的手段和方法 Download PDF

Info

Publication number
HK1201471A1
HK1201471A1 HK15102080.0A HK15102080A HK1201471A1 HK 1201471 A1 HK1201471 A1 HK 1201471A1 HK 15102080 A HK15102080 A HK 15102080A HK 1201471 A1 HK1201471 A1 HK 1201471A1
Authority
HK
Hong Kong
Prior art keywords
ahr
cancer
tdo
cells
kyn
Prior art date
Application number
HK15102080.0A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Platten
Christiane OPITZ
Wolfgang Wick
Ulrike LITZENBURGER
Original Assignee
Deutsches Krebsforschungszentrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum filed Critical Deutsches Krebsforschungszentrum
Publication of HK1201471A1 publication Critical patent/HK1201471A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11017—Indole 2,3-dioxygenase (1.13.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15102080.0A 2011-09-07 2012-09-07 用於治疗和/或预防天然ahr配体依赖性癌症的手段和方法 HK1201471A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531861P 2011-09-07 2011-09-07
US61/531,861 2011-09-07
PCT/EP2012/067504 WO2013034685A1 (en) 2011-09-07 2012-09-07 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer

Publications (1)

Publication Number Publication Date
HK1201471A1 true HK1201471A1 (zh) 2015-09-04

Family

ID=46832380

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102080.0A HK1201471A1 (zh) 2011-09-07 2012-09-07 用於治疗和/或预防天然ahr配体依赖性癌症的手段和方法

Country Status (15)

Country Link
US (1) US9593062B2 (enExample)
EP (1) EP2753315B1 (enExample)
JP (1) JP6047160B2 (enExample)
KR (1) KR20140074330A (enExample)
CN (1) CN104023713A (enExample)
AU (1) AU2012306285B2 (enExample)
BR (1) BR112014004937A2 (enExample)
CA (1) CA2846275C (enExample)
ES (1) ES2626015T3 (enExample)
HK (1) HK1201471A1 (enExample)
IL (1) IL231107A (enExample)
MX (1) MX348941B (enExample)
RU (1) RU2640913C2 (enExample)
WO (1) WO2013034685A1 (enExample)
ZA (1) ZA201401011B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2953065B2 (ja) 1990-12-28 1999-09-27 石川島播磨重工業株式会社 宇宙飛翔体
EP3492094A1 (en) 2013-08-30 2019-06-05 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3186371B1 (en) 2014-08-29 2024-08-14 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
WO2017151860A1 (en) 2016-03-02 2017-09-08 Broard Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CN107510694B (zh) * 2016-06-16 2022-03-29 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN106214673A (zh) * 2016-08-31 2016-12-14 深圳市第二人民医院 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途
WO2018085775A1 (en) * 2016-11-04 2018-05-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
JP7269917B2 (ja) * 2017-08-17 2023-05-09 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7432851B2 (ja) 2018-04-16 2024-02-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトキヌレニナーゼ酵素及びその使用
RU2699932C1 (ru) * 2018-11-14 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития рака печени у экспериментальных животных
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
JP2023510797A (ja) * 2020-01-10 2023-03-15 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤及びその使用
CN114019164B (zh) * 2020-12-31 2023-11-21 中国科学院生态环境研究中心 筛选抗胶质瘤药物的方法和试剂盒
CN112807305A (zh) * 2020-12-31 2021-05-18 中国科学院生态环境研究中心 Ch223191在抑制肿瘤细胞迁移中的应用
CN114470238A (zh) * 2022-03-25 2022-05-13 华中科技大学同济医学院附属协和医院 AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
JP4587652B2 (ja) * 2002-09-09 2010-11-24 株式会社フラバミン 新規フラボノイド化合物及びその利用
CN1744887A (zh) * 2003-02-04 2006-03-08 株式会社益力多本社 乳癌耐性蛋白抑制剂
WO2007128723A1 (en) * 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg Ah receptor antagonists
WO2010008427A1 (en) 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas

Also Published As

Publication number Publication date
CA2846275C (en) 2019-07-16
CA2846275A1 (en) 2013-03-14
RU2014104696A (ru) 2015-10-20
ZA201401011B (en) 2018-07-25
IL231107A (en) 2017-11-30
US20140294860A1 (en) 2014-10-02
EP2753315B1 (en) 2017-03-01
ES2626015T3 (es) 2017-07-21
EP2753315A1 (en) 2014-07-16
AU2012306285B2 (en) 2017-05-18
WO2013034685A1 (en) 2013-03-14
BR112014004937A2 (pt) 2017-06-20
MX2014002776A (es) 2014-11-25
JP6047160B2 (ja) 2016-12-21
CN104023713A (zh) 2014-09-03
IL231107A0 (en) 2014-04-30
RU2640913C2 (ru) 2018-01-12
JP2014526450A (ja) 2014-10-06
KR20140074330A (ko) 2014-06-17
MX348941B (es) 2017-07-04
US9593062B2 (en) 2017-03-14
AU2012306285A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
HK1201471A1 (zh) 用於治疗和/或预防天然ahr配体依赖性癌症的手段和方法
Zheng et al. CD 155 knockdown promotes apoptosis via AKT/Bcl‐2/Bax in colon cancer cells
Zhao et al. GAS5 suppresses malignancy of human glioma stem cells via a miR-196a-5p/FOXO1 feedback loop
Diedrich et al. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation
JP5651331B2 (ja) 結腸直腸癌の治療におけるプロガストリン阻害剤
Mujcic et al. Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3
Zhan et al. lncRNA HOTAIR upregulates autophagy to promote apoptosis and senescence of nucleus pulposus cells
US20240141004A1 (en) Treatment of smc mediated disease
Anania et al. Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells
CN102921007B (zh) 防治胰岛素抵抗和糖尿病的方法和试剂
Li et al. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β‐catenin signaling
Chen et al. PRMT1 potentiates chondrosarcoma development through activation of YAP activity
Liu et al. Identification of Circ-FNDC3B, an overexpressed circRNA in abdominal aortic aneurysm, as a regulator of vascular smooth Muscle cells
Tangseefa et al. Human ACVR1C missense variants that correlate with altered body fat distribution produce metabolic alterations of graded severity in knock-in mutant mice
Chen et al. Hsa_circ_0060927 participates in the regulation of Caudatin on colorectal cancer malignant progression by sponging miR‐421/miR‐195‐5p
Zhang et al. The engrailed‐1 gene stimulates brown adipogenesis
Xu et al. Breast metastatic tumors in lung can be substituted by lung-derived malignant cells transformed by alternative splicing H19 lncRNA
EP2243828A1 (en) Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy
Zhao et al. Circ_0082878 contributes to prostate cancer progression via the miR‐455‐3p/WTAP axis
Qian et al. PFOA exposure promotes prostate cancer progression by enhancing autophagy through m6A modification of MAPK15 mRNA
CN116699135B (zh) 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用
KR101062167B1 (ko) Ｋｉｒ2.2 억제제를 포함하는 암 치료용 조성물
Shi et al. LncRNA GLTC targets LDHA for succinylation and enzyme activity to promote differentiated thyroid cancer progression and radioiodine resistance
Henriques et al. Let us know how access to this document benefits you.
WO2005021729A2 (en) Inhibiting cellular proliferation by way of mixed lineage kinases